Table 4. Outcomes of palliative HIPEC for malignant ascites.

Year	Author	N	Tumor	Agent(s)	Technique	Response (%)	Median survival [range]
2006	Garofalo	14	Varied	Cisplatin and doxorubicin or mitomycin	Laparoscopic	100	203 days [21-667]
2008	Facchiano	5	Gastric	Mitomycin and cisplatin	Laparoscopic	100	89 days [33-144]
2008	Patriti	1	Mesothelioma	Cisplatin and doxorubicin	Laparoscopic	100	6 months
2009	Valle	52	Varied	Cisplatin and doxorubicin or mitomycin	Laparoscopic	98	98 days [21-796]
2010	Ba	16	Gastric	5-fluorouracil and oxaliplatin	Laparoscopic	88	5 months [2-9]
2013	Ba	62	Ovarian	Cisplatin and doxorubicin	Laparoscopic	93	8 months [2-20]
			Gastrointestinal	Mitomycin	B-ultrasound guided	94	9 months [2-30]
2014	Randle	299	Varied	Mitomycin, carboplatin, oxaliplatin, cisplatin,	Open	93	5.3 months*

*, incomplete cytoreduction, non-low grade appendiceal cancers. HIPEC, hyperthemic intraperitoneal chemoperfusion.